Do you have metastatic or incurable, recurrent head and neck cancer? If so, you may be able to participate in a research study to find out if a new investigational drug, in combination with pembrolizumab, can help people with advanced head and neck cancer.

In this study, we want to find out if a medicine called Olaparib works as well as the usual treatment for ovarian cancer. We also want to see if this medicine can help stop the cancer from growing or coming back.

The purpose of this research study is to look at a program that includes expert review of your tumor genetic test results. We want to see if this program can help your doctor identify better treatments or suitable clinical trials for your cancer. This is a hybrid decentralized study where some if not all assessments may be performed remotely or close to your home.

This is a study of an investigational drug called YL201 as a possible treatment for advanced solid tumors. YL201 is thought to work by interrupting DNA replication in cancer cells, via focused delivery of the cytotoxic agent to the cancer cell. YL201 has shown some anti-cancer effects against cancer cells in the laboratory and in experimental animals. The main purpose of this study is to learn how safe the study drug and how well the study drug works.

This research is being done in participants who have Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer, to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab). Toripalimab and bevacizumab have been approved by the Food and Drug Administration (FDA) to treat other cancers, but not Liver cancer. Casdozokitug has not been approved by the FDA to treat any cancers.

The purpose of this research is to see if an experimental vaccine, which is created from your tumor tissue and dendritic cells isolated from your blood, can be an effective therapy when given after your standard treatment of surgery, chemotherapy, and radiation.

Have you been diagnosed with anaplastic thyroid cancer? If so, you might be able to take part in a study to look at the effectiveness of taking cemiplimab and XL092 before and after surgery for your cancer.

The purpose of this research is to measure the safety and effectiveness of ivonescimab compared to pembrolizumab. Ivonescimab is an antibody designed to block proteins that help cancer cells grow and spread, and by blocking these proteins may potentially slow cancer progression.

In this study, we are looking at a medicine called ZE50-0134 that might help treat people with relapsed and refractory CLL, SLL, or certain low-grade lymphomas. We want to see if taking different amounts of this medicine in capsule form is safe for patients.

Have you been diagnosed with metastatic cutaneous melanoma? Have you previously been treated for your melanoma, or maybe it can't be removed? If so, you might be eligible to take part in a study to compare how well a new drug, IMA203, can treat your cancer compared to your physician's choice of treatment.